- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03763266
Low Residue Diet During 3 Days vs 1 Day Prior Colonoscopy
Low Residue Diet 3 Days Versus 1 Day as Preparation for Colonoscopy: a Randomized Controlled Trial
Colonoscopy is the gold-standard for the evaluation of the colorectal mucosa. Colonoscopy quality indicators are the adenoma detection rate, the rate of cecal intubation and the bowel preparation.
The role of diet in preparing for colonoscopy is not fully established. Currently there is not enough evidence available to choice between 3 days of low residue diet versus 1 day.
The research hypothesis is that the low residue diet offers a non-inferior bowel preparation and an improved tolerance.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Barcelona
-
Sabadell, Barcelona, Spain, 08208
- Hospital Parc Tauli
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants in the colorectal cancer screening program that give consent
Exclusion Criteria:
- Contraindication for colonoscopy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1 day low residue diet
Patients are instructed to complete a low residue diet exclusively one day prior the colonoscopy.
|
Patients are interviewed and instructed by a nurse prior the colonoscopy.
They receive oral and written dietary information.
In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Other Names:
|
ACTIVE_COMPARATOR: 3 days low residue diet
Patients are instructed to complete a low residue diet three days prior the colonoscopy.
|
Patients are interviewed and instructed by a nurse prior the colonoscopy.
They receive oral and written dietary information.
In case of morbidity associated with bad preparation they are given bisacodyl the night before the colonoscopy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bowel preparation
Time Frame: During the colonoscopy
|
Measured with the Boston Bowel Preparation Scale from 0 until 9. 9 represents an excellent preparation.
|
During the colonoscopy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diet tolerance
Time Frame: It is reported before entering the endoscopy room. Regarding the 3 or 1 days on low fiber diet depending on which study group is the participant.
|
Using Likert scale.
From 1 to 5, lower is better tolerance.
|
It is reported before entering the endoscopy room. Regarding the 3 or 1 days on low fiber diet depending on which study group is the participant.
|
Preparation tolerance
Time Frame: It is reported before entering the endoscopy room. Regarding the 3 or 1 day on bowel preparation depending on which study group is the participant.
|
Using Likert scale.
From 1 to 5, lower is better tolerance.
|
It is reported before entering the endoscopy room. Regarding the 3 or 1 day on bowel preparation depending on which study group is the participant.
|
Adenoma detection rate
Time Frame: up to 2 weeks after colonoscopy depending on pathology department workload.
|
Proportion of colonoscopies with detection of colorectal cancer or adenoma excluding distal hyperplastic
|
up to 2 weeks after colonoscopy depending on pathology department workload.
|
Endoscopic diagnosis
Time Frame: It is assessed during the colonoscopy and will be reported the same day.
|
Final endoscopic diagnosis.
For example; normal, diverticulosis, polyps, colorectal cancer, etc.
|
It is assessed during the colonoscopy and will be reported the same day.
|
Cecum intubation rate
Time Frame: It will be calculated through study completion, approximately 1 year, for all the study period using all participants having the colonoscopy done
|
Cecum intubation will be assessed during each colonoscopy if the endoscope reaches the cecum.
|
It will be calculated through study completion, approximately 1 year, for all the study period using all participants having the colonoscopy done
|
Intubation time
Time Frame: it is assessed from the start of the colonoscopy until cecum is reached (1 day)
|
time lapse from the start of the exploration until cecum is reached.
|
it is assessed from the start of the colonoscopy until cecum is reached (1 day)
|
Withdrawal time
Time Frame: it is assessed from at the beginning of the withdrawal of the colonoscope until the colonoscopy is finished. (procedure)
|
Time lapse between cecum withdrawal the end of the exploration.
|
it is assessed from at the beginning of the withdrawal of the colonoscope until the colonoscopy is finished. (procedure)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Eva Martínez, PhD, Corporacio Sanitaria Parc Tauli
- Principal Investigator: Salvador Machlab, MD, Corporacio Sanitaria Parc Tauli
- Study Director: Rafel Campo, PhD, Corporacio Sanitaria Parc Tauli
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Gastroenteritis
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Inflammatory Bowel Diseases
- Adenoma
- Colonic Diseases
Other Study ID Numbers
- 2017308
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage IUnited States, Japan, Italy, Spain
-
NuCana plcCompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States, France, United Kingdom
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
The Queen Elizabeth HospitalNovartis; AmgenCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalAustralia
-
Novartis PharmaceuticalsCompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
ProgenaBiomeRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal SarcomaUnited States
-
Pawel KalinskiNational Cancer Institute (NCI)CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, ColorectalUnited States
-
Jeremy MeyerUniversity Hospital, Geneva; Hôpital Fribourgeois; Spital Biel, SwitzerlandNot yet recruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Adenocarcinoma | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Neoplasms, Benign
-
Bristol-Myers SquibbNovartisActive, not recruitingColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal CarcinomaItaly, United States, Canada, Spain, Argentina, Australia, Belgium, Chile, Czechia, Germany
-
City of Hope Medical CenterRecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Disorders | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Polyp | Colorectal Neoplasms Malignant | Colorectal Adenomatous Polyp | Colorectal Cancer Stage I | Colorectal Adenoma... and other conditionsUnited States, Italy, China, Spain, Japan
Clinical Trials on 1 day low residue diet
-
Portuguese Oncology Institute, CoimbraCompletedColonic Neoplasms | Colon DiseasePortugal
-
Changhai HospitalThe First Affiliated Hospital with Nanjing Medical University; First Affiliated... and other collaboratorsCompleted
-
Cedars-Sinai Medical CenterRecruitingImplementing a Low Fiber Diet vs. Regular Diet in Postoperative Colorectal Patients With IleostomiesIleostomy; Complications | Bowel Obstruction | Postoperative IleusUnited States
-
University of Roma La SapienzaCompletedCesarean Section ComplicationsItaly
-
michal rollUnknown
-
Newcastle UniversityNewcastle-upon-Tyne Hospitals NHS TrustCompleted
-
Hospital Parc Taulí, SabadellCompletedBowel Cancer | Colonoscopy | Bowel CleansingSpain
-
Cedars-Sinai Medical CenterCompleted
-
Hospital Parc Taulí, SabadellHospital Mutua de Terrassa; Consorci Sanitari de TerrassaTerminatedColorectal Cancer | Colon Adenoma | Colon PolypSpain
-
National Taiwan University HospitalCompletedDietary ModificationTaiwan